Paragon Capital Management Ltd purchased a new position in shares of Eli Lilly And Co (NYSE:LLY) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,888 shares of the company’s stock, valued at approximately $203,000.

Several other institutional investors have also recently modified their holdings of LLY. Morgan Stanley increased its stake in shares of Eli Lilly And Co by 37.8% during the second quarter. Morgan Stanley now owns 4,473,537 shares of the company’s stock worth $381,727,000 after acquiring an additional 1,227,888 shares during the period. BlackRock Inc. grew its position in Eli Lilly And Co by 1.3% during the second quarter. BlackRock Inc. now owns 66,644,897 shares of the company’s stock worth $5,686,808,000 after buying an additional 864,451 shares during the period. Investec Asset Management LTD grew its position in Eli Lilly And Co by 49.6% during the second quarter. Investec Asset Management LTD now owns 2,528,279 shares of the company’s stock worth $215,738,000 after buying an additional 838,271 shares during the period. Smith Asset Management Group LP acquired a new position in Eli Lilly And Co during the second quarter worth about $65,407,000. Finally, Unigestion Holding SA acquired a new position in Eli Lilly And Co during the second quarter worth about $64,279,000. Institutional investors and hedge funds own 76.17% of the company’s stock.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 7,000 shares of the company’s stock in a transaction dated Thursday, October 4th. The shares were sold at an average price of $114.64, for a total value of $802,480.00. Following the sale, the senior vice president now owns 45,224 shares of the company’s stock, valued at $5,184,479.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Alfonso G. Zulueta sold 6,000 shares of the company’s stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $106.31, for a total transaction of $637,860.00. Following the completion of the sale, the senior vice president now directly owns 55,224 shares in the company, valued at approximately $5,870,863.44. The disclosure for this sale can be found here. Insiders sold 1,881,684 shares of company stock worth $133,274,076 in the last ninety days. Insiders own 0.11% of the company’s stock.

LLY has been the topic of several recent analyst reports. Morgan Stanley upped their target price on shares of Eli Lilly And Co from $93.00 to $102.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 31st. TheStreet lowered shares of Eli Lilly And Co from a “b” rating to a “c+” rating in a research report on Friday, August 24th. Guggenheim initiated coverage on shares of Eli Lilly And Co in a research report on Monday, October 8th. They set a “buy” rating on the stock. Cantor Fitzgerald restated a “buy” rating and set a $128.00 target price on shares of Eli Lilly And Co in a research report on Wednesday, October 17th. Finally, Barclays restated an “overweight” rating and set a $112.00 target price (up from $107.00) on shares of Eli Lilly And Co in a research report on Tuesday, September 18th. Nine research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $111.19.

Shares of NYSE LLY opened at $112.21 on Friday. Eli Lilly And Co has a 12-month low of $73.69 and a 12-month high of $116.61. The stock has a market capitalization of $116.23 billion, a price-to-earnings ratio of 26.22, a price-to-earnings-growth ratio of 1.75 and a beta of 0.29. The company has a current ratio of 1.91, a quick ratio of 1.09 and a debt-to-equity ratio of 0.83.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter in the prior year, the firm earned $1.05 earnings per share. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. On average, equities analysts predict that Eli Lilly And Co will post 5.57 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be issued a $0.5625 dividend. This represents a $2.25 annualized dividend and a dividend yield of 2.01%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 52.57%.

TRADEMARK VIOLATION WARNING: “1,888 Shares in Eli Lilly And Co (LLY) Purchased by Paragon Capital Management Ltd” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/11/10/1888-shares-in-eli-lilly-and-co-lly-purchased-by-paragon-capital-management-ltd.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: How Do You Make Money With Penny Stocks?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.